A proper understanding of this duality is essential for the development of strategies that shift the balance towards effective antitumor immunity, paving the way for usage of IL-33/ST2 signalling axis as both a biomarker and a therapeutic target in personalized breast cancer treatment. This evidence concerns the gene IL1RL1 and breast cancer.